Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10284/8590 |
Resumo: | Some repeats of three or more nucleotides in tandem, which are present in a gene or in its vicinity, tend to increase in number and for this reason are called dynamic mutations. These triplet repeats are unstable and can expand from one generation to the next. According to the expansion size, an unaffected individual can carry a pre-mutation that will expand through generations leading to the development of triplet repeat expansion diseases. The increase in the number of repeats over time leads to earlier development and increased severity of symptoms in affected individuals in successive generations. Although there is still no treatment for this type of disease, several strategies are under investigation. Here, we describe treatment approaches for triplet repeat expansion diseases that have been developed over recent years, using DNA or RNA molecules as targets. Some of these strategies have the potential for future use in gene therapy for trinucleotide repeat disorders. |
id |
RCAP_803d0648e21f48443af4265149a2eccc |
---|---|
oai_identifier_str |
oai:bdigital.ufp.pt:10284/8590 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat DiseaseTreatment of trinucleotide repeat diseasesRNA interferenceAntisense oligonucleotidesExperimental therapiesMyotonic DystrophyHuntington diseaseSome repeats of three or more nucleotides in tandem, which are present in a gene or in its vicinity, tend to increase in number and for this reason are called dynamic mutations. These triplet repeats are unstable and can expand from one generation to the next. According to the expansion size, an unaffected individual can carry a pre-mutation that will expand through generations leading to the development of triplet repeat expansion diseases. The increase in the number of repeats over time leads to earlier development and increased severity of symptoms in affected individuals in successive generations. Although there is still no treatment for this type of disease, several strategies are under investigation. Here, we describe treatment approaches for triplet repeat expansion diseases that have been developed over recent years, using DNA or RNA molecules as targets. Some of these strategies have the potential for future use in gene therapy for trinucleotide repeat disorders.Repositório Institucional da Universidade Fernando PessoaCardoso, Inês Lopes2020-03-02T16:32:46Z2020-02-28T16:09:39Z2018-01-01T00:00:00Z2018-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10284/8590engcv-prod-36872610.21926/obm.genet.1803025info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-06T02:07:58Zoai:bdigital.ufp.pt:10284/8590Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:45:28.245788Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
title |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
spellingShingle |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease Cardoso, Inês Lopes Treatment of trinucleotide repeat diseases RNA interference Antisense oligonucleotides Experimental therapies Myotonic Dystrophy Huntington disease |
title_short |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
title_full |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
title_fullStr |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
title_full_unstemmed |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
title_sort |
Experimental DNA - or RNA-Directed therapies for Trinucleotide Repeat Disease |
author |
Cardoso, Inês Lopes |
author_facet |
Cardoso, Inês Lopes |
author_role |
author |
dc.contributor.none.fl_str_mv |
Repositório Institucional da Universidade Fernando Pessoa |
dc.contributor.author.fl_str_mv |
Cardoso, Inês Lopes |
dc.subject.por.fl_str_mv |
Treatment of trinucleotide repeat diseases RNA interference Antisense oligonucleotides Experimental therapies Myotonic Dystrophy Huntington disease |
topic |
Treatment of trinucleotide repeat diseases RNA interference Antisense oligonucleotides Experimental therapies Myotonic Dystrophy Huntington disease |
description |
Some repeats of three or more nucleotides in tandem, which are present in a gene or in its vicinity, tend to increase in number and for this reason are called dynamic mutations. These triplet repeats are unstable and can expand from one generation to the next. According to the expansion size, an unaffected individual can carry a pre-mutation that will expand through generations leading to the development of triplet repeat expansion diseases. The increase in the number of repeats over time leads to earlier development and increased severity of symptoms in affected individuals in successive generations. Although there is still no treatment for this type of disease, several strategies are under investigation. Here, we describe treatment approaches for triplet repeat expansion diseases that have been developed over recent years, using DNA or RNA molecules as targets. Some of these strategies have the potential for future use in gene therapy for trinucleotide repeat disorders. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-01-01T00:00:00Z 2018-01-01T00:00:00Z 2020-03-02T16:32:46Z 2020-02-28T16:09:39Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10284/8590 |
url |
http://hdl.handle.net/10284/8590 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
cv-prod-368726 10.21926/obm.genet.1803025 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130320810803200 |